UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~February~~May 45, 2022

KYTO TECHNOLOGY AND LIFE SCIENCE, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		000-50390		65-~~108-6538~~1086538
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

13050 La Paloma Road, Los Altos Hills, CA 94022

(Address of Principal Executive Offices, and Zip Code)

650-204-7896

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3 8.0201.~~Unregistered~~ ~~Sales~~Other ~~of Equity Securities~~Events.

OnTermination ~~February 4, 2022, Kyto Technology & Life Sciences, Inc. (the “Company”) issued 3,000,000 shares~~ of ~~the~~Tender ~~Company’s Class~~Offer ~~B3 Preferred Stock at a purchase price of $0.80 per share, resulting in aggregate proceeds to the Company of $2,400,000.~~

On ~~February~~May 45, 2022, the Board of Directors of the Company ~~issued~~(the ~~276,094~~“Board”) ~~shares~~unanimously ofdetermined ~~Class~~to Bterminate ~~Shares~~the atCompany’s previously aannounced ~~purchase~~tender ~~price~~offer of(the ~~$0.80~~“Tender ~~per~~Offer”) ~~share,~~to ~~resulting~~amend inand ~~aggregate~~exercise outstanding warrants for shares of common stock ~~proceeds~~(“Shares”). In determining to terminate the ~~Company~~Tender Offer, the Board considered factors related to reassessment of ~~$220,875~~offering conditions.

The ~~foregoing~~Tender ~~issuances~~Offer ~~were~~was ~~exempt~~made ~~from~~pursuant to the ~~registration~~Tender ~~requirements~~Offer ofStatement on Schedule TO that the Company originally filed with the U.S. Securities and ~~Act~~Exchange ofCommission ~~1933~~on April 1, 2022, as amended. As a result of this termination, ~~pursuant~~no toOriginal ~~Section~~Warrants ~~4(a)(2) thereof~~will asbe aamended, ~~transaction~~and byall Election anForms ~~issuer~~previously tendered and not ~~involving~~withdrawn awill ~~public~~be ~~offering~~cancelled.

Item 9.01.

Financial Statements and Exhibits.

Exhibit		Description
99.1		Press release dated May 5, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KYTO TECHNOLOGY AND LIFE SCIENCE, INC.	~~KYTO TECHNOLOGY AND LIFE SCIENCE, INC.~~
	Date: February 8, 2022	By:	/s/ Paul Russo
Date: May 6, 2022	By:	/s/ Paul Russo
		Paul Russo Chief Executive Officer	~~Paul Russo Chief Executive Officer~~

Filing Compare · Kyto Technology & Life Science, Inc.